Elisabeth J Driessen1, Mieke J Aarts2, Gerbern P Bootsma3, Judith G van Loon4, Maryska L Janssen-Heijnen5. 1. Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, the Netherlands. Electronic address: research@viecuri.nl. 2. Netherlands Cancer Registry, Netherlands Comprehensive Cancer Organisation, Utrecht, the Netherlands. 3. Department of Pulmonology, Zuyderland Medical Centre, Heerlen, the Netherlands. 4. MAASTRO Clinic, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, the Netherlands. 5. Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, the Netherlands; Department of Epidemiology, Maastricht University Medical Centre, GROW School for Oncology and Developmental, Maastricht, the Netherlands.
Abstract
BACKGROUND: This study aimed to describe trends over time regarding disparities in treatment and relative survival (RS) between younger and older patients with non-small cell lung cancer (NSCLC). METHODS: All patients diagnosed with pathologically verified NSCLC in 1990-2014 were included from the Netherlands Cancer Registry (n=187,315). Treatment and RS (adjusted for sex, histology and treatment) were analyzed according to age group (<70 years versus ≥70 years), stage and five-year period of diagnosis. RESULTS: Between 1990 and 2014, five-year RS increased from 17 to 22% among younger patients and from 12 to 16% among elderly. The application of surgery increased over time for elderly with stage I NSCLC, decreased for elderly with stage II, and was stable but higher for younger patients. Disparities in RS between age groups with stage I became smaller since 2000-2004, but did not change over time for stage II. For stage III and IV, both age groups showed strong increases over time in chemoradiotherapy and chemotherapy from 2000 onwards, although considerably less among elderly. One-, three- and five-year RS increased more strongly over time for the younger group leading to larger disparities between age groups with stage III or IV NSCLC. CONCLUSION: More curative-intent treatment and improved RS for NSCLC were seen over time, but were less profound among elderly. Disparities herein between age groups seemed to become smaller over time for stage I NSCLC, did not change for stage II, and were widening for stage III and IV at the expense of elderly. Future prospective studies should focus on optimizing treatment selection and outcomes for elderly.
BACKGROUND: This study aimed to describe trends over time regarding disparities in treatment and relative survival (RS) between younger and older patients with non-small cell lung cancer (NSCLC). METHODS: All patients diagnosed with pathologically verified NSCLC in 1990-2014 were included from the Netherlands Cancer Registry (n=187,315). Treatment and RS (adjusted for sex, histology and treatment) were analyzed according to age group (<70 years versus ≥70 years), stage and five-year period of diagnosis. RESULTS: Between 1990 and 2014, five-year RS increased from 17 to 22% among younger patients and from 12 to 16% among elderly. The application of surgery increased over time for elderly with stage I NSCLC, decreased for elderly with stage II, and was stable but higher for younger patients. Disparities in RS between age groups with stage I became smaller since 2000-2004, but did not change over time for stage II. For stage III and IV, both age groups showed strong increases over time in chemoradiotherapy and chemotherapy from 2000 onwards, although considerably less among elderly. One-, three- and five-year RS increased more strongly over time for the younger group leading to larger disparities between age groups with stage III or IV NSCLC. CONCLUSION: More curative-intent treatment and improved RS for NSCLC were seen over time, but were less profound among elderly. Disparities herein between age groups seemed to become smaller over time for stage I NSCLC, did not change for stage II, and were widening for stage III and IV at the expense of elderly. Future prospective studies should focus on optimizing treatment selection and outcomes for elderly.
Authors: Elisabeth J M Driessen; Judith G M van Loon; Huub A Maas; Anne-Marie C Dingemans; Maryska L G Janssen-Heijnen Journal: Lung Date: 2018-04-12 Impact factor: 2.584
Authors: J L Cruz-Bermúdez; C Parejo; F Martínez-Ruíz; J C Sánchez-González; A Ramos Martín-Vegue; A Royuela; A Rodríguez-González; E Menasalvas-Ruiz; M Provencio Journal: Clin Transl Oncol Date: 2019-03-12 Impact factor: 3.405
Authors: Melissa J J Voorn; Loes P A Aerts; Gerbern P Bootsma; Jacques B Bezuidenhout; Vivian E M van Kampen-van den Boogaart; Bart C Bongers; Dirk K de Ruysscher; Maryska L G Janssen-Heijnen Journal: Lung Date: 2021-03-10 Impact factor: 2.584
Authors: Christine M Cramer-van der Welle; Lotte van Loenhout; Ben Eem van den Borne; Franz Mnh Schramel; Lea M Dijksman Journal: BMJ Open Date: 2021-01-15 Impact factor: 2.692
Authors: Eric D Miller; James L Fisher; Karl E Haglund; John C Grecula; Meng Xu-Welliver; Erin M Bertino; Kai He; Peter G Shields; David P Carbone; Terence M Williams; Gregory A Otterson; Jose G Bazan Journal: Radiat Oncol Date: 2018-10-05 Impact factor: 3.481
Authors: Sophie Pilleron; Helen Gower; Maryska Janssen-Heijnen; Virginia Claire Signal; Jason K Gurney; Eva Ja Morris; Ruth Cunningham; Diana Sarfati Journal: BMJ Open Date: 2021-03-10 Impact factor: 2.692
Authors: Alessandra Buja; Michele Rivera; Anna De Polo; Eugenio di Brino; Marco Marchetti; Manuela Scioni; Giulia Pasello; Alberto Bortolami; Vincenzo Rebba; Marco Schiavon; Fiorella Calabrese; Giovanni Mandoliti; Vincenzo Baldo; PierFranco Conte Journal: Thorac Cancer Date: 2020-11-21 Impact factor: 3.500